24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
Pharmaceutical manufacturing is energy-intensive, audit-heavy, and increasingly measured against climate expectations. That is why pharmaceutical carbon neutrality has moved from CSR reporting to plant strategy, supplier selection, and capital expenditure planning across Russia and the CIS. Procurement teams now face carbon questions alongside lead times and continuity risk. QA teams see sustainability controls intersect with GMP (Good Manufacturing Practice) and documentation discipline. Production leaders are expected to cut emissions without increasing deviation risk or threatening throughput.
For many organisations, the starting point is a credible greenhouse gas (GHG) inventory across Scope 1, 2, and 3 emissions. Scope 3 is often the largest share, encompassing suppliers, logistics, and product life-cycle impacts. That reality makes decarbonisation a cross-functional programme rather than a facilities-only project. A peer-reviewed review of pharmaceutical company targets and strategies highlights the breadth of approaches and the pressure to address company-wide emissions, including value-chain impacts.
Many firms use external frameworks to structure targets and reporting. The Science Based Targets initiative (SBTi) publishes standards and guidance for setting emissions reduction targets lined up with climate science, which procurement and finance teams increasingly reference when assessing supplier credibility.
Sustainability is also evident in regulatory signals. In the EU, an Environmental Risk Assessment (ERA) is mandatory within marketing authorisation applications for human medicines, placing environmental considerations alongside safety and quality. While ERA is not a carbon accounting tool, it reinforces the direction of travel: environmental impact is becoming part of product stewardship and regulatory readiness.
Across the Eurasian Economic Union, inspection planning guidance continues to emphasise risk-based approaches to GMP oversight, which matters when sites introduce process changes, new utilities, or alternative materials during decarbonisation programmes. Carbon projects that alter HVAC, solvents, water systems, or cleaning regimes need validation-grade change control from day one.
Most carbon plans in pharma manufacturing cluster around a handful of operational levers. Below is what we see repeatedly in projects that balance sustainability with GMP, throughput, and cost control.
ISO 14064-1 is widely used as a framework for designing, developing, managing, reporting, and verifying an organisation’s GHG inventory, thereby helping teams move from estimates to defensible figures.
Carbon neutrality efforts rarely succeed through a single isolated “green project”. They land through hundreds of practical decisions across the production lifecycle, with ROI tied to reliability and compliance.
Production equipment and processing technologies
Electrification and controls upgrades tend to perform well where they also reduce downtime. Variable-speed drives, improved temperature control, and lower-pressure-drop filtration can reduce energy use and stabilise quality.
Raw materials, APIs, and excipients
API (Active Pharmaceutical Ingredient) synthesis often drives a large share of embedded emissions. Procurement teams increasingly request information on suppliers' energy mix, solvent recovery practices, and transport modes. The same scrutiny is spreading into adjacent categories, including nutraceutical ingredients, where extract processing and logistics can be carbon-intensive.
Cleanrooms and laboratories
HVAC is often a dominant energy consumer. Changes require careful qualification, as air change rates, pressure cascades, and environmental monitoring are directly linked to contamination control and batch-release confidence.
Packaging and serialisation
Lightweight materials, smarter line layouts, and reduced reject rates can lower emissions while supporting track-and-trace requirements. Any packaging change still needs stability, compatibility, and regulatory assessment.
Carbon reduction is effective only when engineering, QA, procurement, and automation share a common evidence base. Pharmtech & Ingredients supports this by covering the full pharmaceutical production lifecycle, from ingredients to finished dosage equipment and packaging systems, with suppliers aligned with GMP, ISO standards, and regional requirements.
At the Pharmtech Expo (24–27 November 2026, Crocus Expo, Pavilion 2, Eurasia), teams can evaluate equipment, compare solution providers, and pressure-test sustainability claims through technical seminars and peer discussion. This is also where decarbonisation connects to measurable plant outcomes: fewer deviations, faster changeovers, stronger data integrity, and lower total cost per batch.
For exhibitors, Pharmtech Expo sponsorship is most effective when framed around evidence rather than promises. Think energy data, validation packs, utility consumption benchmarks, and case studies that procurement and engineering teams can take to an investment committee.
If your team is planning a structured visit, treat the show as a working session rather than a browsing day. Many visitors use it as their annual pharma manufacturing expo checkpoint for suppliers, audit-ready technologies, and contract services across the CIS and wider Eurasian market. For timing and programme updates, your primary source is Pharmtech's latest news.
Pharma carbon neutrality will be won through disciplined execution: verified baselines, risk-based change control, and supplier accountability. Plants that treat sustainability as part of quality culture tend to move faster, because they document decisions clearly and validate changes properly.
Interested in exhibiting? Submit an enquiry to reserve your space in the Contract Services zone. Bring your decarbonisation-ready capabilities, validation support, and measurable performance data for decision-makers who are actively upgrading sites across Russia and the CIS.
